More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001 plus standard of care chemotherapy combinations from ASCEND expansion cohorts in several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers; on track to report initial data from hundreds of patients in mid-2027 Potential to start the first of multiple CR-001 Phase 3 studies in early 2028 Crescent and Kelun-Biotech rapidly advancing development of CR-001 as next generation immuno-oncology (IO) backbone: multiple sacituzumab tirumotecan (sac-TMT) + CR-001 Phase 2 studies ongoing in NSCLC and other solid tumors in more than 700 patients, with initial data expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned Global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, on track to commence dosing this quarter; initial data expected in the second half 2027 Phase 1/2 trial of CR-003 (SKB105), an ITGB6-targeted ADC, ongoing in China; initial data expected in Q1 2027 Anticipate more than 2,000 patients dosed across portfolio by mid-2027 WALTHAM, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, as well as the initiation of additional antibody-drug conjugate (ADC) combination studies with CR-001.
